PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25106115-6	2014	In Huh7 replicon cells treated with ASA, we found decreased levels of iNOS mRNA, iNOS protein and nitrosylated protein levels at 48-72 h. ASA exposure also reduced the transactivation of the iNOS promoter in HCV replicon cells at 48 h, and this was partly due to the decrease in the affinity of transcription factor C/EBP-beta for its binding site in the iNOS promoter.	Aspirin	138-141	CCAAT enhancer binding protein beta	Homo sapiens	316-326	
25106115-6	2014	In Huh7 replicon cells treated with ASA, we found decreased levels of iNOS mRNA, iNOS protein and nitrosylated protein levels at 48-72 h. ASA exposure also reduced the transactivation of the iNOS promoter in HCV replicon cells at 48 h, and this was partly due to the decrease in the affinity of transcription factor C/EBP-beta for its binding site in the iNOS promoter.	Aspirin	36-39	CCAAT enhancer binding protein beta	Homo sapiens	316-326	
15199473-4	2003	Aspirin and salicylate at therapeutic concentrations inhibit COX-2 protein expression through interference with binding of CCAAT/enhancer binding protein beta (C/EBPbeta) to its cognate site on COX-2 promoter/enhancer.	Aspirin	0-7	CCAAT enhancer binding protein beta	Homo sapiens	123-158	
24243637-9	2014	Treatment of adipocyte fractions or SGBS adipocytes with metformin or acetylsalicylic acid, which target C/EBPbeta and NF-kappaB/RelA signaling, attenuated the IL-1alpha induction of 11beta-HSD1 (P<=.002).	Aspirin	70-90	CCAAT enhancer binding protein beta	Homo sapiens	105-114	
15199473-4	2003	Aspirin and salicylate at therapeutic concentrations inhibit COX-2 protein expression through interference with binding of CCAAT/enhancer binding protein beta (C/EBPbeta) to its cognate site on COX-2 promoter/enhancer.	Aspirin	0-7	CCAAT enhancer binding protein beta	Homo sapiens	160-169	
15199473-7	2003	These recent studies provide new insight into the pharmacological actions of aspirin and salicylate preparations and implicate C/EBPbeta as a potential target for therapy of inflammation and tissue injury.	Aspirin	77-84	CCAAT enhancer binding protein beta	Homo sapiens	127-136	
11278846-5	2001	These findings indicate that contrary to the current view that salicylate acts via inhibition of nuclear factor kappaB the pharmacological actions of aspirin and salicylates are mediated by inhibiting CCAAT/enhancer-binding protein beta binding and transactivation.	Aspirin	150-157	CCAAT enhancer binding protein beta	Homo sapiens	201-236	
11205285-5	2000	RESULTS: aspirin, at plasma attainable levels, induced NF-IL6 DNA-binding activity, and increased MDR1 mRNA expression (by up to 140%), as well as the expression of P-gp, in Molt-4 cells.	Aspirin	9-16	CCAAT enhancer binding protein beta	Homo sapiens	55-61